Cadrenal Therapeutics Common StockNASDAQ: CVKD

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

20 January 2023

Next earnings report:

N/A

Last dividends:

N/A

Next dividends:

N/A
$14.94 M
-68%vs. 3y high
22%vs. sector
-vs. 3y high
-vs. sector
-54%vs. 3y high
75%vs. sector
-vs. 3y high
-vs. sector

Price

pre-market | 90 min ago
$14.00-$0.99(-6.60%)

Dividend

No data over the past 3 years
No data over the past 3 years

Analysts recommendations

Institutional Ownership

CVKD Latest News

Cadrenal Therapeutics Announces Exercise of Warrants for $4.7 Million Gross Proceeds
prnewswire.com01 November 2024 Sentiment: POSITIVE

PONTE VEDRA, Fla., Nov. 1, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc., ("Cadrenal" or the "Company") (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) for certain rare medical conditions, today announced the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 285,715 shares of common stock of the originally issued in July 2023, having an exercise price of $26.25 per share, at a reduced exercise price of $16.50 per share.

CADRENAL THERAPEUTICS JOINS CORPORATE COUNCIL OF ANTICOAGULATION FORUM
prnewswire.com23 October 2024 Sentiment: POSITIVE

Participation Reinforces Cadrenal's Commitment to Innovation, Education and Improved Patient Outcomes with Anticoagulation Therapy PONTE VEDRA, Fla. , Oct. 23, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company developing tecarfarin, a new vitamin K antagonist (VKA) designed to improve anticoagulation for patients with implanted cardiac devices or rare cardiovascular conditions, today announced its membership in the Corporate Council of the Anticoagulation Forum (AC Forum).

Cadrenal Therapeutics Announces Upcoming Type-B FDA Meeting in September to Discuss Tecarfarin Trial in LVAD Patients
prnewswire.com22 August 2024 Sentiment: POSITIVE

PONTE VEDRA, Fla. , Aug. 22, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage, next-generation Vitamin K Antagonist (VKA) oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with implanted cardiac devices and those with rare cardiovascular conditions, announced today that it will be engaging with the U.S. Food and Drug Administration (FDA) in early September for a Type-B meeting to discuss its clinical trial for tecarfarin in LVAD patients.

Published Findings Highlight Tecarfarin's Potential and Reinforce Need for Better Anticoagulation Therapy in LVAD Patients
prnewswire.com20 August 2024 Sentiment: POSITIVE

Analysis features the growing need to evolve anticoagulation therapy beyond warfarin to avoid gastrointestinal bleeding, a significant and common complication for left ventricular assist device (LVAD) patients resulting in expensive hospitalizations   Tecarfarin, a novel vitamin K antagonist (VKA), uses a different metabolic pathway than warfarin, the most commonly used anticoagulant for LVAD patients, and may offer more stable and effective anticoagulation PONTE VEDRA, Fla. , Aug. 20, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage, next-generation VKA oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with implanted cardiac devices or rare cardiovascular conditions, today highlighted a manuscript that was recently peer-reviewed and published in the Journal of Cardiac Failure evaluating the relationship between time in therapeutic range, or TTR, management quality and LVAD patient clinical outcomes.

Cadrenal Therapeutics Provides Second Quarter 2024 Corporate Update
prnewswire.com07 August 2024 Sentiment: POSITIVE

PONTE VEDRA, Fla. , Aug. 7, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage, next-generation Vitamin K Antagonist (VKA) oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with implanted cardiac devices and those with rare cardiovascular conditions, today provided a corporate update coinciding with the filing of its Quarterly Report on Form 10-Q for the quarter ended June 30, 2024.

Cadrenal Therapeutics to Present at the Emerging Growth Conference on June 12, 2024
prnewswire.com11 June 2024 Sentiment: POSITIVE

PONTE VEDRA, Fla. , June 11, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage, new-generation Vitamin K Antagonist (VKA) oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions, today announced that the Company will be participating in the Emerging Growth Conference on June 12, 2024.

Why Is Cadrenal Therapeutics (CVKD) Stock Up 71% Today?
InvestorPlace12 July 2023 Sentiment: POSITIVE

Cadrenal Therapeutics (NASDAQ: CVKD ) stock is taking off on Wednesday despite a lack of news from the biopharmaceutical company. There have been no new press releases from Cadrenal Therapeutics that explain why its stock is up today.

The 3 Hottest IPOs to Buy Before They Soar
InvestorPlace28 June 2023 Sentiment: POSITIVE

It has been a tough, quiet year in the market for initial public stock offerings (IPOs) which has investors eagerly searching for high potential IPOs. In the global IPO landscape, the first quarter of 2023 witnessed a total of 299 IPOs, raising an amount of $21.5 billion.

What type of business is Cadrenal Therapeutics Common Stock?

Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc. was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.

What sector is Cadrenal Therapeutics Common Stock in?

Cadrenal Therapeutics Common Stock is in the Healthcare sector

What industry is Cadrenal Therapeutics Common Stock in?

Cadrenal Therapeutics Common Stock is in the Biotechnology industry

What country is Cadrenal Therapeutics Common Stock from?

Cadrenal Therapeutics Common Stock is headquartered in United States

When did Cadrenal Therapeutics Common Stock go public?

Cadrenal Therapeutics Common Stock initial public offering (IPO) was on 20 January 2023

What is Cadrenal Therapeutics Common Stock website?

https://www.cadrenal.com

Is Cadrenal Therapeutics Common Stock in the S&P 500?

No, Cadrenal Therapeutics Common Stock is not included in the S&P 500 index

Is Cadrenal Therapeutics Common Stock in the NASDAQ 100?

No, Cadrenal Therapeutics Common Stock is not included in the NASDAQ 100 index

Is Cadrenal Therapeutics Common Stock in the Dow Jones?

No, Cadrenal Therapeutics Common Stock is not included in the Dow Jones index

When was Cadrenal Therapeutics Common Stock the previous earnings report?

No data

When does Cadrenal Therapeutics Common Stock earnings report?

Next earnings report date is not announced yet